Skip to main navigation
Overview
Newsroom
News Releases
Corporate Statements
Multimedia Resources
Events & Presentations
Events
Presentations
Financials
SEC Filings
Annual Reports
Stock Information
Stock Quote & Chart
Analyst Coverage
Investor FAQs
Corporate Governance
Governance Documents
Committee Composition
Leadership
Code of Business Conduct
Corporate Responsibility
Contact the Board
Top bar
Biogen.com
Information Request
Sign up for Alerts
Search
Search
Search
News
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe
News
New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ and ELOCTATE™ Across Multiple Hemophilia Populations
SEC Filings
Form 4
News
The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX™ Effectively Controlled Bleeding in Hemophilia B Patients
SEC Filings
Form 4
News
Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting
News
Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™
SEC Filings
Form 4
News
Biogen Idec to Present at the 2013 Deutsche Bank BioFEST
SEC Filings
Form 4
Pagination
Page 1
Next page
››
Filter by gallery
No facets
Your selection
Clear all
2013
Remove
Filter by category
Filter by category
Filter by category
Filter by category
Filter by type
Filter by tags
Filter by form group
Filter by content year
(-)
2013
(172)
Filter by content type
SEC filing
(111)
News
(61)
Tools
Print Page
Stockholder Communications
E-mail Alerts
FAQs
Facebook
Twitter
LinkedIn
Google+
